| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | TPCA-1 | CTRPv2 | pan-cancer | AAC | -0.079 | 0.02 |
| mRNA | navitoclax:gemcitabine (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.081 | 0.02 |
| mRNA | BRD-K48477130 | CTRPv2 | pan-cancer | AAC | 0.13 | 0.02 |
| mRNA | QL-VIII-58 | GDSC1000 | pan-cancer | AAC | 0.11 | 0.02 |
| mRNA | thalidomide | CTRPv2 | pan-cancer | AAC | 0.12 | 0.02 |
| mRNA | CHM-1 | CTRPv2 | pan-cancer | AAC | -0.075 | 0.02 |
| mRNA | ruxolitinib | CTRPv2 | pan-cancer | AAC | -0.079 | 0.02 |
| mRNA | THZ-2-102-1 | GDSC1000 | pan-cancer | AAC | -0.072 | 0.02 |
| mRNA | AZD7762 | CTRPv2 | pan-cancer | AAC | -0.075 | 0.02 |
| mRNA | ML083 | CTRPv2 | pan-cancer | AAC | 0.089 | 0.02 |